SCHEMBL2801973

SCHEMBL2801973

COC(=O)c1ccc(Br)c(OCCOCC(F)(F)F)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 3/20 0.53
MAPT P10636 5/20 0.43
KDM4E B2RXH2 4/20 0.42
HTT P42858 3/20 0.42
KMT2A Q03164 2/20 0.42
L3MBTL1 Q9Y468 2/20 0.40
TDP1 Q9NUW8 1/20 0.40
TTR P02766 1/20 0.40
ALDH1A1 P00352 3/20 0.40
HPGD P15428 2/20 0.40
RAB9A P51151 1/20 0.40
MEN1 O00255 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C19 P33261 1/20 0.39
LMNA P02545 3/20 0.39
MRGPRX4 Q96LA9 3/20 0.38
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA7 P43166 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1934261 0.89 NOTUM (0.58) NOTUMMAPTKDM4EHTTKMT2A
SCHEMBL980319 0.87 NOTUM (0.52) NOTUMMAPTKDM4EHTTKMT2A
SCHEMBL2803332 0.87 ALDH1A1 (0.48) NOTUMKMT2AL3MBTL1ALDH1A1MRGPRX4
SCHEMBL2802155 0.87 NOTUM (0.52) NOTUMMAPTKDM4EHTTKMT2A
SCHEMBL27140070 0.85 MAPT (0.46) NOTUMMAPTKDM4EHTTKMT2A
SCHEMBL30823363 0.85 MAPT (0.46) NOTUMMAPTKDM4EHTTKMT2A
SCHEMBL1344274 0.84 MAPT (0.50) NOTUMMAPTKDM4EHTTKMT2A
SCHEMBL12068781 0.82 NOTUM (0.49) NOTUMMAPTKDM4EKMT2AL3MBTL1
SCHEMBL2804095 0.81 NOTUM (0.48) NOTUMMAPTKMT2AL3MBTL1TDP1
SCHEMBL3901339 0.81 MAPT (0.48) NOTUMMAPTKDM4EKMT2AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010132016-A1 BIS-(SULFONYLAMINO) DERIVATIVES FOR TREATMENT OF PAIN AND INFLAMMATION ASTRAZENECA AB (SE) 2010-11-18 WO disclosed
WO-2010132016-A1 BIS-(SULFONYLAMINO) DERIVATIVES FOR TREATMENT OF PAIN AND INFLAMMATION ASTRAZENECA AB (SE) 2010-11-18 WO disclosed
US-20100292279-A1 Bis-(Sulfonylamino) Derivatives in Therapy ASTRAZENECA AB (SE) 2010-11-18 US disclosed
US-20100292279-A1 Bis-(Sulfonylamino) Derivatives in Therapy ASTRAZENECA AB (SE) 2010-11-18 US disclosed
US-20100292279-A1 Bis-(Sulfonylamino) Derivatives in Therapy ASTRAZENECA AB (SE) 2010-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100292279-A1 Bis-(Sulfonylamino) Derivatives in Therapy PTGER1, SULT2A1, SULT1E1 NOTUM 954/4885MAPT 1012/4885KDM4E 2095/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.